The urine biomarkers TIMP2 and IGFBP7 can identify patients who will experience severe acute kidney injury following a cardiac arrest: A prospective multicentre study
| Autor: | Yoann Zerbib, Michel Slama, Kada Klouche, Dimitri Titeca-Beauport, Julien Maizel, Momar Diouf, Delphine Daubin, Clément Brault, Jonathan Chelly, Christophe Vinsonneau |
|---|---|
| Přispěvatelé: | CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier de Béthune (CH Béthune), GHT de l'Artois |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty IGFBP7 medicine.medical_treatment [SDV]Life Sciences [q-bio] Urology Urine 030204 cardiovascular system & hematology Emergency Nursing Severity of Illness Index 03 medical and health sciences 0302 clinical medicine Predictive Value of Tests medicine Humans In patient Prospective Studies Renal replacement therapy Stage (cooking) Aged Aged 80 and over Tissue Inhibitor of Metalloproteinase-2 business.industry Acute kidney injury 030208 emergency & critical care medicine Acute Kidney Injury Middle Aged medicine.disease Heart Arrest 3. Good health Insulin-Like Growth Factor Binding Proteins Urine biomarkers Emergency Medicine Female Cardiology and Cardiovascular Medicine business Biomarkers |
| Zdroj: | Resuscitation Resuscitation, Elsevier, 2019, 141, pp.104-110. ⟨10.1016/j.resuscitation.2019.06.008⟩ |
| ISSN: | 0300-9572 |
| Popis: | Aim To determine whether the urine biomarkers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) can identify patients who will develop severe acute kidney injury (AKI) soon after cardiac arrest. Methods We performed a prospective, multicentre study in three French ICUs. The performance of [TIMP-2]*[IGFBP7] was assessed for urine samples collected a median [IQR] of 240 [169–315] minutes post-collapse. The primary end-point was severe AKI (KDIGO stage 3), within 48 h of admission. Results Of the 115 patients analyzed, 32 (28%) developed severe AKI. Eleven of these required renal replacement therapy. The median [IQR] baseline [TIMP-2]*[IGFBP7] level was higher in patients who developed severe AKI (1.57 [0.80–6.62] (ng/ml)2/1000) than in those who did not (0.17 [0.05–0.59] (ng/ml)2/1000; p Conclusion Urine [TIMP-2]*[IGFBP7] effectively identify patients with a risk of severe AKI. Below a cut-off of 0.39 (ng/ml)2/1000, the risk of severe AKI is low. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect